Compare iShares Silver Trust (SLV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs TransMedics Group Inc — how do they compare? iShares Silver Trust trades at $54.9 (market cap $29.02B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: iShares Silver Trust is far larger — about 10.6× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 16,510,334). Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and TransMedics Group Inc for 24 Days on average.
| SLV | TMDX | |
|---|---|---|
Market Cap | $29.02B | $2.74B |
Volume | 16,510,334 | 949,331 |
52-Week High | $105.57 | $150.42 |
52-Week Low | $42.40 | $61.99 |
Typical Hold Time | 89 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV trades at $54.85, up 1.91% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows minimal operational activity with $0 revenue and $2.17M net income in 2024, while assets surged to $13.4B from previous years. Recent news highlights silver's volatility amid Fed policy uncertainty and rising Treasury yields.
Outlook remains cautious due to bearish technicals and macroeconomic pressures on precious metals. Investment opportunity exists for contrarian buyers given oversold conditions, but risks include continued Fed tightening and dollar strength. Silver's dual role as monetary and industrial metal adds volatility exposure.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
